In cancer cells driven by oncogenic KRAS, genes relevant for G2/M-phases of the cell cycle, like Aurora A kinase, were found to be linked to FRA1 [59] and expose a therapeutic vulnerability. This evidence concerns the gene KRAS and cancer.